I think these 2 dividend stocks could be among the best UK shares to buy today

Buying these two UK dividend stocks right now could produce more than just a worthwhile passive income in 2021, in my opinion.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Dividend stocks could be a means of obtaining a passive income in 2021. However, they may offer more than just a generous income return.

Income shares could become more popular in an era where low interest rates may remain in place for a prolonged period of time. Furthermore, today’s high-yielding shares could offer good value for money, as well as dividend growth potential over the coming years.

With that in mind, here are two FTSE 100 dividend shares that could be worth buying at the present time.

An improving outlook relative to other dividend stocks

SSE could become increasingly attractive relative to other dividend stocks in the next few years. The renewables-focused utility company recently updated the market on its performance. It remains on track to meet its guidance to deliver dividend growth that’s at or above inflation over the next few years.

This could make the stock more appealing over the medium term because of the potential for inflation to move higher. A loose monetary policy may mean the price level increases at a faster pace in future than it has done in the past. Alongside the company’s 5.4% yield, this could make it an attractive FTSE 100 share to buy at the present time.

A high-yielding UK share at a relatively low price

While many UK shares have risen sharply in the recent stock market rally, GlaxoSmithKline (GSK) isn’t among them. Its shares have continued to fall over recent months so that it’s now among the highest-yielding dividend stocks in the FTSE 100.

Its 6% dividend yield could make it attractive from an income perspective, since many FTSE 100 shares have considerably lower yields at the present time. Certainly, its dividends have failed to rise in recent years on a per share basis.

They could even come under pressure over the coming years as the company embarks on major structural and organisational changes. However, those changes could catalyse its financial performance over the long run, and may be priced in to the company’s valuation via a relatively high yield.

Potential risks from buying income stocks

Of course, dividend stocks don’t guarantee investors will receive any passive income. They could, for example, experience challenging operating conditions that restrict their ability to pay out profit to investors. Similarly, they may decide to retain capital in what remains a tough economic outlook. This could have a detrimental impact on their income prospects.

However, with other assets potentially offering low returns in a low interest rate environment, dividend shares such as GSK and SSE could be attractive as part of a diverse portfolio of stocks. When combined with other companies, they may offer an attractive passive income that grows over the coming years. This could increase their appeal on a relative basis and allow them to command higher share prices that translate into impressive total returns for investors.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Peter Stephens owns shares of GlaxoSmithKline and SSE. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »